Adjuvant Aromatase Inhibitor Therapy in Early Breast Cancer: What Factors Lead Patients to Discontinue Treatment?
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Adjuvant Aromatase Inhibitor Therapy in Early Breast Cancer: What Factors Lead Patients to Discontinue Treatment?
Authors
Keywords
-
Journal
TUMORI
Volume 101, Issue 5, Pages 469-473
Publisher
SAGE Publications
Online
2015-06-25
DOI
10.5301/tj.5000376
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer.
- (2017) Richard G. Gray et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update
- (2014) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Interruption and Non-Adherence to Long-Term Adjuvant Hormone Therapy Is Associated with Adverse Survival Outcome of Breast Cancer Women - An Asian Population-Based Study
- (2014) Kun-Pin Hsieh et al. PLoS One
- Predictors of Aromatase Inhibitor Discontinuation as a Result of Treatment-Emergent Symptoms in Early-Stage Breast Cancer
- (2012) N. Lynn Henry et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
- (2012) Christina Davies et al. LANCET
- Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer
- (2011) Larissa Nekhlyudov et al. BREAST CANCER RESEARCH AND TREATMENT
- Use of tamoxifen and aromatase inhibitors in a large population-based cohort of women with breast cancer
- (2011) L Huiart et al. BRITISH JOURNAL OF CANCER
- Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer
- (2010) Dawn L. Hershman et al. BREAST CANCER RESEARCH AND TREATMENT
- Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis
- (2010) Myrthe P. P. van Herk-Sukel et al. BREAST CANCER RESEARCH AND TREATMENT
- Early Discontinuation and Nonadherence to Adjuvant Hormonal Therapy in a Cohort of 8,769 Early-Stage Breast Cancer Patients
- (2010) Dawn L. Hershman et al. JOURNAL OF CLINICAL ONCOLOGY
- American Society of Clinical Oncology Clinical Practice Guideline Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer
- (2010) Harold J. Burstein et al. Journal of Oncology Practice
- Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study
- (2009) Karine Briot et al. BREAST CANCER RESEARCH AND TREATMENT
- Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer
- (2008) C McCowan et al. BRITISH JOURNAL OF CANCER
- Predictors of Tamoxifen Discontinuation Among Older Women With Estrogen Receptor–Positive Breast Cancer
- (2007) Cynthia Owusu et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search